Strong Momentum in Pharma Services and Commercialization

Houlihan Lokey is excited to announce that it has advised on seven transactions in the pharma services and commercialization sectors thus far in 2022, making it one of the most active advisors in the space.

We have been privileged to advise a number of clients within sectors along the entire drug development lifecycle, including medical communications, medical affairs, market access, life sciences consulting, healthcare marketing, medical animation, and data and technology.

Our continued activity in the sector has provided us with unparalleled industry observations, real-time insights, and unique perspectives on relevant investors. Should you be exploring opportunities in the market or considering alternatives, please feel free to reach out to our team.

Click on each transaction to learn more.

About Houlihan Lokey

Houlihan Lokey (NYSE:HLI) is a global investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, and financial and valuation advisory. The firm serves corporations, institutions, and governments worldwide with offices in the Americas, Europe, the Middle East, and the Asia-Pacific region. Independent advice and intellectual rigor are hallmarks of the firm’s commitment to client success across its advisory services. Houlihan Lokey is the No. 1 investment bank for global M&A transactions under $1 billion, the No. 1 M&A advisor for the past eight consecutive years in the U.S., the No. 1 global restructuring advisor for the past nine consecutive years, and the No. 1 global M&A fairness opinion advisor over the past 25 years, all based on number of transactions and according to data provided by Refinitiv.